Context Therapeutics (NASDAQ:CNTX – Get Free Report) posted its earnings results on Thursday. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01, reports.
Context Therapeutics Trading Up 4.9 %
Shares of CNTX opened at $0.81 on Friday. The firm has a market cap of $60.60 million, a price-to-earnings ratio of -0.88 and a beta of 2.06. The stock has a 50 day moving average of $0.86 and a 200-day moving average of $1.45. Context Therapeutics has a 52 week low of $0.64 and a 52 week high of $2.75.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on CNTX shares. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Context Therapeutics in a research note on Friday. D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a research note on Friday. JMP Securities initiated coverage on Context Therapeutics in a research note on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 target price for the company. Finally, Citizens Jmp raised Context Therapeutics to a “strong-buy” rating in a report on Wednesday, January 8th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $6.17.
About Context Therapeutics
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
See Also
- Five stocks we like better than Context Therapeutics
- Business Services Stocks Investing
- Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets
- 5 discounted opportunities for dividend growth investors
- Cybersecurity Stocks Surge as $32B Deal Reshapes the Industry
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
